Related Experiment Video
Updated: Feb 4, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond
Sarika N Rao1,2, Maria E Cabanillas3
1MedStar Washington Hospital Center, Washington, DC.
Abstract:
Thyroid cancer, with the exception of anaplastic thyroid cancer, typically has very favorable outcomes with the standard therapy. However, those that persist, recur, or metastasize are associated with a worse prognosis. Targeted therapy with kinase inhibitors has shown promise in advanced cases of thyroid cancer, and currently five drug regimens are approved for use in clinical practice in the treatment of differentiated, medullary, and anaplastic thyroid cancer, with more options in the pipeline. However, one of the greatest dilemmas is when and how to initiate one of these drugs, and this is discussed herein.
Insights
Thyroid cancer outcomes are favorable, but advanced or recurrent cases require targeted therapy. This review discusses when and how to initiate kinase inhibitor treatments for better patient prognosis.
Area of Science:
- Oncology
- Pharmacology
Background:
- Thyroid cancer generally has a good prognosis with standard treatment, except for anaplastic thyroid cancer.
- Persistent, recurrent, or metastatic thyroid cancer presents a significant challenge with a poorer prognosis.
Purpose of the Study:
- To discuss the optimal timing and strategy for initiating targeted therapy in advanced thyroid cancer.
- To provide guidance on the clinical application of kinase inhibitors for thyroid cancer management.
Main Methods:
- Review of current clinical practice and emerging data on targeted therapies for thyroid cancer.
- Discussion of approved kinase inhibitor regimens and those in development.
Main Results:
- Five drug regimens targeting kinase pathways are currently approved for differentiated, medullary, and anaplastic thyroid cancer.
- Numerous additional targeted therapy options are under investigation and development.
Conclusions:
- While standard therapy is effective for most thyroid cancers, targeted therapies are crucial for advanced or refractory disease.
- Deciding when and how to implement kinase inhibitor therapy remains a key clinical dilemma requiring careful consideration.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Gene Therapy
Standards of Care II
Standards of Care I
Group Therapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

